Compare Microsoft (MSFT) vs 10X Genomics Inc (TXG) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Microsoft vs 10X Genomics Inc — how do they compare? Microsoft trades at $523.75 (market cap $3.93T), while 10X Genomics Inc trades at $78.6 (market cap $9.92B). The key difference: Microsoft is far larger — about 396.2× 10X Genomics Inc's market cap, and Microsoft pays a 0.74% dividend while 10X Genomics Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Microsoft for 142 Days and 10X Genomics Inc for 92 Days on average.
| MSFT | TXG | |
|---|---|---|
Market Cap | $3.93T | $9.92B |
Volume | 16,040,951 | 9,372,166 |
Sector | Technology | Health |
52-Week High | $542.07 | $97.74 |
52-Week Low | $352.83 | $11.48 |
Typical Hold Time | 142 Days | 92 Days |
Enterprise Value | $3.91T | $9.44B |
Dividend Yield | 0.74% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Microsoft (MSFT) trades at $522.61, down 1.26% on the day, amid a bullish technical setup with strong moving average signals and key support at $522. The company reported robust fundamentals with Q2 2026 EPS of $4.74 beating estimates, revenue growth to $281.72B in 2025, and net income margins of 40.31%. Recent news highlights AI leadership and Azure momentum, though RSI levels suggest overbought conditions.
Outlook remains positive with an 81.71% analyst buy rating and a $571.76 consensus price target, implying ~9% upside. Risks include elevated capital expenditure concerns and competitive pressures in AI. Strong cash flow generation and a declining debt-to-asset ratio support long-term growth, but investors should monitor execution on AI investments and macroeconomic headwinds.
10x Genomics (TXG) trades at $77.28, down 4.19% on the day, amid a bearish technical signal. The company reported revenue of $642.82M in 2025, with a net loss of $43.54M, though it has beaten EPS estimates for three consecutive quarters. Recent news highlights the launch of its Atera spatial biology platform and a patent victory, signaling innovation and market strength. Cash flow from operations improved to $136.05M in 2025, indicating better operational efficiency.
The outlook is cautiously optimistic, with strong product demand and improving margins offering upside potential. However, persistent losses, high valuation multiples, and competitive pressures present significant risks. Analyst consensus is mixed, with a $74.30 price target slightly below the current price, reflecting uncertainty about near-term profitability.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Microsoft
Microsoft Corporation develops, manufactures, licenses, sells, and supports software products. The Company offers operating system software, server application software, business and consumer applications software, software development tools, and Internet and intranet software. Microsoft also develops video game consoles and digital music entertainment devices.
Read more on MSFT →About 10X Genomics Inc
10x Genomics Inc is a life science technology company based in the United States. Its solutions include instruments, consumables, and software for analyzing biological systems. The product portfolio of the company includes Chromium Controller, Reagent Kits, 10x Compatible Products, and Informatics Software among others. The majority of its revenue is generated from consumables.
Read more on TXG →
